BTEC:LSE:LSE-iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (USD)

ETF | Others |

Last Closing

USD 6.92

Change

-0.03 (-0.43)%

Market Cap

N/A

Volume

0.06M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

-4.75 (-2.49%)

USD 1,607.29B
0R1O:LSE Amazon.com Inc.

-4.75 (-2.49%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

-0.84 (-0.70%)

USD 618.20B
0R1I:LSE NVIDIA Corp.

-0.84 (-0.70%)

USD 618.20B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

-0.05 (-0.38%)

USD 572.76B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

-0.05 (-0.38%)

USD 572.76B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

-0.08 (-0.45%)

USD 572.76B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

-0.08 (-0.45%)

USD 572.76B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B

ETFs Containing BTEC:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.46% 54% F 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.46% 53% F 57% F
Trailing 12 Months  
Capital Gain 22.02% 68% D+ 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.02% 67% D+ 66% D+
Trailing 5 Years  
Capital Gain 58.12% 70% C- 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 58.12% 69% C- 72% C
Average Annual (5 Year Horizon)  
Capital Gain 5.34% N/A N/A 57% F
Dividend Return 5.34% N/A N/A 56% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 18.69% N/A N/A 53% F
Risk Adjusted Return 28.55% N/A N/A 59% D-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike